Independent clinical study confirms strong performance of fluidlab 2

We are pleased to share the results of an independent clinical study published in Clinical Chemistry and Laboratory Medicine (CCLM), evaluating the anvajo fluidlab 2 in line with the latest European urinalysis guidelines. The study analyzed 450 routine patient samples and demonstrates that fluidlab 2 delivers results closely matching manual expert microscopy for the most clinically relevant urine particles. In particular, red and white blood cells, key indicators for urinary tract and kidney diseases, were reliably detected, confirming the device’s clinical accuracy.

The study highlights the advantages of fluidlab 2’s compact, near-patient format, which combines digital holographic microscopy with AI-based particle recognition. This integration allows for standardized, high-quality urinalysis to be performed directly at or near the point of care, enabling faster clinical decision-making without compromising guideline-compliant performance.

While the evaluation confirms strong performance, the authors also note areas for further validation, particularly regarding particles such as bacteria and crystals. These findings underscore the importance of ongoing clinical evaluation and method comparison, driving continuous refinement and innovation in the technology.

Implications for clinical practice:
The study demonstrates that reliable, guideline-oriented urinalysis can now be more accessible in decentralized healthcare settings. By providing near-patient testing with performance equivalent to traditional laboratory methods, the fluidlab 2 supports timely and informed decision-making, improving workflow efficiency and patient care.

The full peer-reviewed article, “Analytical and diagnostic evaluation of the anvajo fluidlab 2 analyzer, a novel urine particle analyzer for clinical application using digital holographic microscopy,” is available at https://doi.org/10.1515/cclm-2025-1202.